Introduction
Brain tumors constitute a solicitous and unsolved problem in the treatment because of inadequacy in bypassing the blood brain barrier (BBB) 1, 2 and mitigation of brain tumor is still the foremost challenging obligation 3 . BBB, a highly lipophilic barrier consist of the vascular structures composed of physical obstacle (tight junctions of astrocytes and endothelial cells), and well organised traffic controller of the metabolic barriers (multidrug resistance (MDR) pathways), that is managing the transport of bioactive materials across the BBB [4] [5] [6] [7] . The Cassette transport pump (p-glycoprotein) shows fundamental role in the drug efflux at the level of BBB 8 .
However, hydrophobic small molecular drugs can be easily transported across the BBB; and diverse attempts have been made to transport active molecules across the BBB 9, 10 . The successful management of brain tumor necessitates the bypassing, inactivate or suppress the metabolic BBB barriers 11 . Therefore, expansion of an efficient system to bear the active molecules across the BBB has been a major challenge in research and stress must therefore be resolute on developing approach that enhances the bioavailability in the central nervous system (CNS).
Nanotechnology indeed exploited in the most of the pharmacological complication of active molecules that results in increment in their therapeutic efficiency [12] [13] [14] [15] . Biocompatible nanostructured systems confess the interactions with biomolecules and interior environment of the cell and may sidestep the highly lipophilic physical obstacle that limits the passage of wide verity of therapeutic agent across BBB [16] [17] [18] . Nowadays surface engineering of nanocarriers for target specific delivery of active molecules have been considered a viable strategy for the improved therapeutic efficacy in the management of brain tumor [19] [20] [21] [22] . Thus, targeting strategies are capable of crossing barriers present in BBB to overcome the limited transport across it. Out of various approaches, adsorptive transcytosis via cationic bovine serum albumin (CBA) has been scrutinize to bypass BBB without influencing the integrity of tight junction at BBB [23] [24] [25] .
Surface modification of NPs finesses the BBB via adsorptive transcytosis where interaction between BSA and cell membrane) at the BBB demonstrate BSA preferentially encourage transport of nanocarriers across BBB [26] [27] [28] [29] .
Methotrexate (MTX), a dihydrofolate reductase (DHFR) inhibitor acting in S-phase of the cell cycle plays a crucial role in the treatment of brain cancer by introducing itself within the folate stacks 30, 31 . However, the inability to deliver MTX across BBB owing to its hydrophilic nature and the distribution of the drug at noncancerous sites has severely compromised its clinical application. Therefore, nanostructured drug delivery vehicles, which are able to bypass BBB and cell membranes of brain tumor cells is an urgent and inevitable requirement for the treatment of brain tumors. United States Food and Drug Administration (US-FDA) approved the biodegradable non-immunogenic, biocompatible polyester polymers such as poly (D,L-lactideco-glycolide) (PLGA) in targeted drug delivery of drugs for various ailments [32] [33] [34] [35] .
The prepared NPs formulation engineered with CBA was physico-chemically characterized and evaluated using in vitro, ex vivo (cell line) and in vivo studies. Moreover, a comparative study of brain uptake of FITC tagged NPs following intravenous injection was confirmed by fluorescence microscopy. In nutshell, the present study with CBA modifiedPLGANPs encapsulated MTX opens new horizon not only to understand the difficulties but also improvement in management of effective treatment of brain cancer.
Materials, methods and Instrumentation

Materials
MTX, bovine serum albumin (BSA), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and (EDC) were purchased from Sigma Aldrich (Germany). PLGA, 50:50), N-hydroxy succinimide (NHS), Di-methyl-sulphoxide (DMSO), PluronicF-68(PF-68), FITC, Triton-X100
were purchased from Himedia, Mumbai, India. Nylon membrane filter (0.22 µm) was purchased from Pall Gelman Sciences (USA). All other reagents and solvents were of analytical grade unless otherwise specified. Ultra-pure deionized water was used through the study.
Preparation of cationic bovine serum albumin (CBA)
CBA was prepared from BSA following the well-established procedure reported earlier with trivial modifications (Feng et al., 2009) . Briefly, 0.5 g of BSA was treated with little exceeding of ethylenediamine (EDA) previously solubilised in conjugation buffer (MES; 0.2 mol/L) at 4±1 °C while being agitate using magnetic stirrer (Remi, India) and the pH was adjusted to 4.7. Supplementary, 50 mg of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) was added and allowed to keep undisturbed for 2 h in dark, at ambient temperature. The reaction was continued by addition of 0.4 ml of acetate buffer (2 mol/L; pH 4.75). Finally, the solution was dialyzed extensively against ultrapure deionised water for 48 h, lyophilized and stored in hermetically sealed container. Further, BSA and CBA were further characterized using NMR (Bruker DRX, USA) and FTIR spectroscopy (Perkin-Elmer, USA).
Fabrication of nanoparticles
The MTX loaded PLGA NPs were prepared in accordance to the solvent-diffusion technique described by Song et al., 2006 36 with slight modifications. Briefly, MTX was dissolved in PBS (pH 7.4)/DMSO. Subsequently, aqueous solution of Pluronic® F-68 (PF-68) (PBS; pH 7.4) was added as a stabilizer to the drug solution. To it 1% w/v PLGA solution (the organic phase; 10 ml) in ethyl acetate was added drop-wise into 20 ml of an aqueous phase consisting drug and stabilizer under regular magnetic agitation (REMI Instrument India). This pre-emulsion was maintained above the melting temperature using a hot water bath and the stirring of high speed was set out to attain a pre-emulsion phase followed by sonication. In addition, a measured volume of ultra-pure deionized water was supplied to the o/w emulsion under gentle stirring to facilitate the diffusion of organic phase into an aqueous solvent leading to the formation of MTX loaded PLGA NPs (MTX-NPs). Subsequently, NPs dispersion was filtered through 0.22 µm membrane filters. Finally, the MTX-NPs dispersion was lyophilized (Heto Drywinner, Denmark, Germany) and stored for further studies. FITC labeled NPs were prepared by co-encapsulation of FITC along with MTX in PLGA NPs.
Fabrication of CBA conjugated MTX loaded PLGA NPs (CBA-MTX-NPs)
Freeze dried MTX-NPs were dispersed in ultra-pure deionized water at a concentration of 20 mg/ml. Subsequently, 50 mg N-hydroxy succinimide (NHS) was added and allowed to be agitated for next 6 h followed by addition of EDC (15 mg) while constant stirring (Magnetic stirrer; Remi, India) for 48 h at ambient temperature. Afterwards, CBA (50 mM) was added while agitating all night (2000 rpm) to facilitate its conjugation with the MTX-NPs. The dispersion was then finally dialyzed against ultra-pure deionized water for 30 min to take away free CBA and other impurities followed by lyophilization (Heto Drywinner, Denmark, Germany).
Characterization of nanoparticles
2.5.1. Measurement of particle size and zeta potential
The average particle size and poly dispersity index (PDI) of MTX-NPs and CBA-MTXNPs was determined by a Zetasizer (DTS ver. 4.10, Malvern Instruments, England). Briefly, nano-particulate sample dispersion was added in polystyrene cuvettes diluted with ultra-pure deionized water and analyzed at a 90° fixed angle. The zeta potential of NPs formulation was measured by determining electrophoretic mobility with a laser-based multiple angle particle electrophoresis analyzer, Malvern Zetasizer (DTS Ver. 4.10, Malvern Instruments, England).
The nanoparticles were suspended in ultra-pure de-ionized water and kept in an electrophoretic cell with an electric field of 15.24 V/cm and the zeta potential was measured.
Scanning electron microscopy
Surface morphology was determined by scanning electron microscope (SEM). In brief, the NPs powder was sprinkled on a double adhesive tape which was stuck on an aluminium stub.
Following this the stubs were coated with gold at a thickness of about 300 Å by using a sputter coater. All NPs and examined under a SEM (LEO 435 VP, Eindhoven Netherlands) at an acceleration voltage of 30 kV and photographs were taken at various magnifications.
Encapsulation efficiency
The drug encapsulation efficiency was estimated using a dialysis method for separating unloaded MTX from the NPs. This was then analyzed spectrophotometrically to indirectly determine the amount of drug bound with the NPs. Momentarily, 5 ml of the MTX-NPs dispersion was placed into a dialysis bag (MWCO 1000 KDa, Himedia, India) and dialyzed against 50 ml of 0.1N NaOH for 60 minutes with magnetic stirring (50 rpm). Samples (0.5 ml)
were withdrawn occasionally and collected into HPLC vials (Himedia, India) until no drug was detected in the receptor compartment 37 . All samples (injection volume -10µl) were quantified for MTX content by HPLC at a flow rate of 1ml/min at 302 nm and at 40°C. Samples were loaded into the HPLC system to quantify the unentrapped amount of MTX, so as to quantify indirectly the amount of entrapped MTX within theNPs [38] [39] [40] . The same exercise was carried out to measure the entrapped drug in CBA conjugated NPs and the quantification was performed using HPLC (Shimadzu, Japan). The reversed phase C 18 column (4.6 mm×250 mm, 5µm) was used for chromatographic separation. The mobile phase was a mixture of buffer (pH 6.0) and acetonitrile at a ratio of 9:1. The buffer consisted of 0.12 M di-sodium hydrogen orthophosphate and 0.03 M citric acid. 41 .
In vitro release study
The ability of NPs to release drugs into external media was determined by conducting the in vitro drug release assay on the developed NPs. The dialysis tube diffusion technique was used to estimate in vitro release of MTX from MTX-NPs and CBA-MTX-NPs. The fixed volume of the prepared nano-particulate formulations (5 ml) were poured into the dialysis tubing (MWCO 1000 KDa), tied at both ends and immersed into receptor media consisting 100 ml of phosphate buffer saline pre-equilibrated at 37±2°C followed by moderate stirring (magnetic stirring;100 rpm). 0.5 ml sample from recipient compartment was withdrawn intermittently and an equal quantity of fresh medium was added after each sample withdrawal in a receptor compartment to maintain a constant sink volume over the experiment. The same practice was adopted for the determination of drug release profile at pH 5.4 (mimicking acidic tumor environment). Samples were analyzed by HPLC using same method described above and the amount of MTX released over time was quantified 41, 42 . Subsequently, the plates were rinsed with ultra-pure deionized water, dried and stained with 50-60 µl of 5%w/v SRB reagent (constructed in 1%v/v acetic acid) for an h. Then, 150 µl of acetic acid was aspirated to remove the excess of SRB reagent. In each well, TRIS was added and wellmixed on a shaker for few minutes. The optical density (OD) of each well was then measured at 490 nm via microplate spectrophotometer (Model 680, Bio-Rad, Japan).
Ex vivo
Cellular uptake assay
Cellular uptake efficiency of NPs was evaluated as a function of ligand using fluorescence activated cell sorters (FACS) instrument (BD Biosciences FACS Aria, Germany) againstC6 glioma cells. Glioma cells were cultured in accordance with the process described under cytotoxicity studies. Briefly, cells were seeded in 6 well plates (Sigma, Germany) at a harvested by adding 1 ml PBS (pH ~7.4) followed by probe sonication for five times to obtain the cell lysate. Finally, cell lysate was centrifuged at 12,000 rpm for 10 min, and the supernatant was subjected to florescence assay using FACS. Same procedure was followed to study the cellular uptake profile after 2 and 6 h 3,44 .
In vivo pharmacokinetic and biodistribution studies
The The organs viz. brain, liver, kidney, heart spleen and tumor were isolated carefully, weighed and stored at −80 °C until experimentation. Afterwards, blood sample was collected from other three animals (n = 6) of each group for 2-8 h intervals, euthanized and different 9 organs were isolated. This exercise was also repeated for last three animals of each group for 8-24 h intervals.
Plasma was separated from blood samples by centrifugation at 10,000 rpm for 15 min.
Afterwards, 100 µl of plasma was filtered into micro-centrifuge tube and same quantity of acetonitrile was added to precipitate the protein.
At the same time, the organs were chopped and homogenized to detach the tissues, vortexed for one minute, and kept undisturbed for 30 min. Tissue homogenates were then treated with100 µl of acetonitrile. Further, the serum and tissue homogenates earlier admixed with acetonitrile were vortexed for 1 min, and subsequently centrifuged at 5000 rpm for 15 min. The supernatant was filtered through a 0.22 µm syringe filter, collected in HPLC vials (Himedia, India), and quantified for MTX content. Quantification of MTX was done in serum as well as in various tissues viz. brain (glioma cells), heart, liver, spleen and kidney was performed by HPLC method as described earlier 41, 47 .
Hemolytic toxicity
Hemolytic study was performed following the procedure described earlier with slight modifications 39, 48 . Briefly, whole human blood samples were collected from a healthy person (with kind consent) and heparinized in HiAnticlot blood collection vials (Himedia, India).
Subsequently, the red blood cells (RBCs) suspension was centrifuged and resuspended in normal saline. Two mL of the RBCs suspension was separately dispersed in normal saline solution producing no hemolysis (served as control '0 % hemolysis') and in distilled water considered to be producing 100% hemolysis. One ml of adequately diluted plain MTX solution, MTX-NPs, and CBA-MTX-NPs were incubated individually with 2 ml RBCs suspension and the volume was made up to 10 ml with normal saline.
The formulations were taken in such amount that the resultant final concentration of MTX was equivalent in every case so as to facilitate the assessment of extent of hemolysis followed by effect of tween 80 (Himedia, Mumbai, India) coating on hemolysis. Further, the formulations were allowed to incubate at 37±1 °C for 30 min, followed by centrifugation at 4000 rpm for 10 min. Subsequently, supernatants were taken and diluted with an equal volume of normal saline and absorbance was measured by UV-Visible spectrophotometer (Schimadzu, 1601 Japan) at 540 nm against normal saline diluted similarly as blank. The percent hemolysis was then determined for each sample by taking absorbance of distilled water which was assumed to be producing 100% hemolysis.
Data analysis
Statistical analysis of the data was articulated as the mean ± S.D and statistical analysis was computed using one-way analysis of variance (ANOVA) with a Tukey-Kramer multiple comparison Post-test using GraphPad InStat™ software (GraphPad Software Inc., San Diego, California). A probability level of p<0.05 was considered to be significant.
Results and discussion
Preparation of CBA
The FTIR spectroscopy of pure BSA (Fig. 1A) shows the distinctive peaks at 3280. (Fig. 1A) . After cationization discrepancy in the FTIR peaks are understandable with elevated intensity at parallel wavelength because of the presence of auxiliary ethylene amine group in CBA incorporated during cationization. Shifting of FTIR peak of -OH groups, C=O stretching, and disappearance of 1388.88 cm −1 (aromatic -C=C-stretching) confirmed the cationization of BSA (Fig. 1B) . In NMR spectroscopy, amine group (-NH 2 ) shows high shielding effect and the obtained spectra of CBA illustrated its characteristic peak at 3.5 ppm which confirms the presence of amine group in CBA (Fig. 2A) .
Preparation of CBA conjugated MTX loaded NPs (CBA-MTX-NPs)
The NPs were fabricated by an emulsification-diffusion method and the carboxylic group of NPs was conjugated to amine functionalities of CBA according to a previously reported method as reported earlier with slight modifications [49] [50] [51] . This technique involved the quick diffusion of solvent across the solvent-lipid phase into aqueous phase followed by evaporation of solvent leading to enhanced rigidity of the NPs. (Fig. 1C) . In NMR Spectra, acidic group (-COOH) demonstrate its peak at deshielded position or away from the reference line of tetra methyl silane in NMR spectra. In NMR spectra of CBA-MTX-NPs, distinguish peak with less intensity at 8.5
ppm indicated that the most of the free carboxylic group get saturated with amine group of CBA, thus confirmed the formation of amide bond between carboxylic groups of MTX-NPs made up of PLGA and amine groups of CBA (Fig. 2 B) .
Characterization of nanoparticles
Size, Zeta Potential and Surface morphology
The average particle size of CBA conjugated MTX-NPs as measured by dynamic light scattering technique was found to be larger than that of unconjugated formulation ( Fig. 3 and Table 1 ). The disparity in the average size may be due to the conjugation of CBA on the surface of MTX-NPs. The average particle size of MTX-NPs was found to be108.3±3.1nm while in case of CBA conjugated formulation it was 120.9±4.4 nm. The mean diameters of NPs were well below 200 nm and these fallouts are in harmony with SEM photographs of the CBA conjugated NPs (Fig. 4A and B) .
Zeta potential is an imperative criterion in order to establish the storage stability of nanometric particulate system. The zeta potential of MTX-NPs and CBA-MTX-NPs formulations was found to be -13.7± 0.4 mV and -5.55± 0.3 mV, respectively (Fig. 3 and Table   1 ). The higher negative magnitude of zeta potential might be ascribed to the -COO (carboxylic) group exist at the surface of polymeric NPs. The lowering of zeta potential value upon CBA conjugation was reasoned to be due to subsequent replacement of -COO group with terminal amine (NH 2 ) groups after protein conjugation 51 . The elevated magnitude of zeta potential offers repulsive inter-particle interaction preventing aggregation of the nanoparticles 52 .
Entrapment Efficiency
MTX-NPs showed appreciably higher entrapment efficiency (79.9±2.4%) as compared to the CBA conjugated NPs (71.3±1.8%) ( Table 1) . Dissolution and subsequent loss of surface adhered MTX from MTX-NPs upon addition of NPs in the medium may be ascribed to the divergence in entrapment efficiency. These outcomes are consistent to the results obtained in earlier investigations 53 .
In vitro drug release profile
In vitro drug release in pH 7.4 and 5.4 on plain and conjugated NPs demonstrated a biphasic drug release pattern suggesting an early burst, followed by a lag phase and a later apparent-zero order phase (Fig. 4C) . MTX release of 20.26±1.58% and 28.9 ±2.45% was attained from CBA-MTX-NPs and MTX-NPs correspondingly in the PBS (pH 7.4). On the other hand, 21.4±1.03% and 33.9 ±1.15% of MTX was found to be released from CBA-MTX-NPs and MTX-NPs, respectively in the acidic media (pH 5.4) until the end of 8 th h (Fig. 4C) . offering a steric hindrance to diffusion of drug 9, 54 .Furthermore, accelerated degradation of PLGA and lessening of ionic interaction between drug and PLGA at an acidic pH might be accountable for faster drug release at lower pH. Acidic pH catalyzes the cleavage of ester linkages in the polymer backbone and augments the erosion of polymeric matrix 55 . As a result, PLGA NPs could be anticipated to afford a pH-stimulating release of entrapped MTX at acidic milieu of tumor and might facilitate ligand mediated transcytosis as well.
Ex vivo studies
Cytotoxicity and cell uptake studies
The cytotoxic response in term of % growth inhibition of free MTX, MTX-NPs and CBA-MTX-NPs was evaluated by SRB assay against C-6 glioma cells. Percent Cellular inhibition response against all formulation was found to be concentration dependent. None of the formulation showed any effect on the survival of cells when the MTX equivalent concentration was below 1 µM, and in all these cases the cell viabilities were found to be well above 90%
survival rate (Fig. 5 A, 
B & C).
Experiments conducted on xenografts model undoubtedly exemplify a dose dependent cytotoxic response that is a decrease in % cell survival with increase in concentration of drug.
Nearly100 % of the cells were killed when concentration of MTX was 100 µM in case of all the formulation. Probably, the cytotoxic action of drug depends upon adequate access of drug in the cell and not merely by its presence in the adjacent milieu of a cell over the incubation period (72 h). In concentration range (1-100 µM) of MTX, the cytotoxic effect was sort out as CBA-MTXNPs > MTX-NPs > CBA+ CBA-MTX-NPs > MTX (Fig. 5 A, B & C) . 
Cellular Uptake Study
Imperatively CBA-MTX-NPs facilitates higher cytotoxic response in C-6 cells, in vivo the ligand anchored formulation would promptly experience transcytosis therefore evading the possibility of marked increase in % cellular uptake effect on C-6 cells as compared to unconjugated formulation and fluorescence marker alone.
The efficacy of cellular uptake as a function of CBA conjugation and incubation time was determined using flow cytometry. Two h post incubation of plain FITC, FITC labeled MTXNPs, FITC labeled CBA-MTX-NPs, and free CBA + FITC labeled CBA-MTX-NPs, the percent fluorescencein C-6 glioma cells was found to be 9.8 ± 2.4%, 14.1 ± 3.1%, 33.6 ± 3.3%, and 11.7 ± 3.2%, respectively (Fig. 5 D) . Fluorescence intensity augmented with time (p≤0.05), which was merely 32.7±2.6%, 51.5±3.2%, 78.6±3.8%, and 39.6±3.3%, respectively after 6 h. The higher uptake of CBA conjugated formulation was possibly due to CBA residues tethered on the 
In vivo pharmacokinetic and biodistribution studies
Biodistribution studies were carried out to examine the efficacy of CBA conjugated NPs in the delivery of anticancer agents to target tumor tissues while circumventing the BBB and also bypass peripheral tissues (kidney, heart, liver, etc.). Following injection of MTX entrapped in NPs, the initial maximum concentration attained was slightly lower than plain MTX (Fig. 6A) . 
Conclusions
NPs are the biocompatible nano-carriers which have been expansively investigated for the delivery of therapeutics. This is the first report of its own kind that offers an insight to use of cationic bovine serum albumin tethered biodegradable polymeric nanostructured carriers for brain tumors exploiting adsorption mediated transcytosis to circumvent the highly lipophilic BBB. The present study discloses CBA functionalized polymeric nanoparticles as proficient vectors to carry large doses of anti-cancer drug for its sustained and targeted delivery. CBA tethered NPs incorporating MTX demonstrated cytotoxicity higher than that of plain MTX on C-6 glioma cells at all the concentration tested. The formulation proficiently navigated huge doses of anti-cancer therapeutic agent across the BBB. The best promising therapeutic response and diminution in annoying side effects may be facilitated by site specific delivery strategy.
Nevertheless, meticulous exercises require to be carried out to attain any unambiguous generalization.
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